SCR-LIP-000569 · Claim · machine-readable JSON →
A new disease-specific Patient Benefit Index for lymphedema and lipedema (PBI-L) was validated (n=301 cross-sectional, n=82 RCT), yielding a mean global benefit score of 2.2±1.0 and correlating with disease-specific HRQoL (FLQA-LK, r=0.31) but not with change in generic EQ-5D-3L.
This single-paper claim was consolidated into general propositions (R-CLM-19); its evidence now sits under:
Claim at a glance
- Type
- clinical association
- Knowledge state
- Emerging
- Evidence certainty
- moderate (GRADE)
- Evidence
- 1 source(s)
- Answers
- 0 question(s)
- Dates
- 2026-11-17 → 2026-11-17
Structured evidence, machine-compiled — not a verdict.
Auto-compiled by the Layer 1 surveillance loop; not yet human-reviewed. anthropic/claude-opus-4.8 · 2026-11-17
Evidence over time
Evidence (1)
- Evaluation of Patient-relevant Outcomes of Lymphedema and Lipedema Treatment: Development and Validation of a New Benefit Tool (2014) ✓ verified — contextual · cross sectional · 2014 · reading confidence: high
“Global and subscale scores correlated with convergent criteria and with change in disease-specific HRQoL, but not with change in generic HRQoL.”
The article develops and validates a measurement instrument involving lymphedema and lipedema combined; it measures treatment benefit and correlates with HRQoL but does not itself test how lipedema specifically affects HRQoL versus controls
Context (PECO)
Answers these questions
- Not yet linked to a question.
Gaps & caveats
Auto-ingested single source; not yet human-reviewed.
Change log
- 2026-11-17 — created · auto-ingested for SQ-LIP-000041
- 2026-11-20 — consolidated · SQ-LIP-000041: evidence moved to SCR-LIP-000783